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DOI 10.1016/j.chembiol.2009.04.002Very few drugs are potent enough to fight
tumors yet gentle enough on the body. To
this eternal dilemma of cancer therapy,
nanotechnology offers a solution: hide
the drug inside tiny packages that break
open only when they reach the tumor.
The drug will then attack only the tumor,
not healthy cells, making it both safer
and more effective. Although this idea of
nanoparticle-based drug delivery is in an
early stage, it has already spawned
a vast range of new formulations. A hand-
ful of them are in clinical use and dozens
of others are in various stages of develop-
ment. ‘‘Nanotechnology is opening up
awhole series of new platforms for cancer
therapeutics,’’ says Anthony Tolcher, MD,
of South Texas Accelerated Research
Therapeutics, a group in San Antonio
that specializes in phase I clinical trials
of cancer drugs. ‘‘This is clearly the most
exciting time in oncology drug develop-
ment.’’
Nanoparticle-based delivery exploits
the so-called enhanced permeability and
retention (EPR) effect associated with
tumors. The idea is to infuse the nanopar-
ticles into the bloodstream, and allow
them to seep out of the leaky blood
vessels in tumors and release their drug
inside the tumor tissue. For this ‘‘passive
targeting’’ to work, the particle has to
meet several criteria. It has to circulate in
the blood for a sufficient period, which
implies a long plasma half-life and low
clearance rate. It should be stable—but
not too stable—for it to remain intact in
the blood but break open inside the
tumor. Thus, the particle’s size becomes
critical: if it’s too small, it will quickly
pass into the kidneys and be eliminated
before it can get to the tumor, whereas
if it is too large, it can’t get into the tumor.
Nanoparticles with a diameter in the
10–100 nm range work best, says Mark
Davis, PhD, of the California Institute of
Technology, who has designed several
nanoparticles including two that are now
in clinical trials.
The earliest attempt at building such
a particle happened back in the 1960s,
when a team of researchers led by Alec
Bangham published a landmark paper
on unilamellar vesicles of phospholipids,
now called liposomes (Bangham et al.,
1965). These forerunners of modern
nanoparticles self-assemble from a lipid
bilayer into microscopic bubbles that are
hydrophilic outside and hydrophobic
inside. Bangham described them in a later
essay as ‘‘pharmacological punching
bags’’ that could perform miracles (Bang-
ham, 1989). Their potential for drug
delivery was obvious: the water soluble
bubbles can encapsulate and deliver
a wide range of molecules, including
highly insoluble ones. (According to one
estimate, poor solubility causes the rejec-
tion of nearly one in two trial pharmaceu-
tical compounds, especially those of
natural origin.) Although early liposomes
disintegrated easily, scientists soon
developed methods to stabilize them.
‘‘That was the true beginning of the nano-
particle era,’’ says Davis.
Thanks to their early start, liposomes
are used formaking three of the four nano-
particle formulations currently approved
by the FDA. Among the best known is
Ortho Biotech’s Doxil, first approved in
1999 for refractory ovarian cancer. The
formulation contains the chemotherapy
drug doxorubicin encapsulated in a lipo-
some stabilized with a coating of polyeth-
yleneglycol. It is reported tohaveaplasma
half-life about 1003 higher and clearance
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bicin. Thanks to these attributes, adminis-
tering thenanoparticle formulation instead
of the free drug increases the drug
concentration in tumor 10-fold. Another
liposome-encapsulated therapeutic that
achievessimilar pharmacokinetic improve-
ments is NeXstar Pharmaceuticals’s
DaunoXome, approved in 1996 for Kapo-
si’s sarcoma.AbraxisBioscience’sAbrax-
ane, approved in 1995 for metastatic
breast cancer, is a special case: a
nanoscale albumin-bound form of the
chemotherapy agent paclitaxel, it is not
considered a true nanoparticle by some
experts, but achieves the same effect of
solubilizing its base drug.
Liposomes have several desirable
traits. Made from harmless natural mate-
rials, they enjoy a long in vivo lifetime and
have been successfully used in many
pharmaceutical applications. However,
as delivery vehicles for cancer drugs,
they have performed only modestly, des-
pite encouraging preclinical data. Few
have been shown to significantly improve
response rate or overall survival com-
pared to the corresponding free drugs.
While they do seem to reduce overall
toxicity, they appear to introduce new
ones in some cases. For instance, in one
trial for breast cancer, Doxil reduced
cardiac toxicity but increased skin
toxicity. Part of the problem with lipo-
somes may be lack of stability, according
to Glen Kwon, PhD, an expert on poly-
meric micelle nanoparticles at the Univer-
sity of Wisconsin at Madison. ‘‘Poorly
soluble chemotherapy drugs tend to leak
out of thembefore they reach their target,’’
he says. ‘‘Thismakes it hard to achieve the
EPR effect.’’ Liposomes also don’t offer
much scope for precise control over the
location and rate of drug release, he adds.
Now a ‘‘second generation’’ of nano-
particle methodologies has emerged,
promising better stability, lower toxicity,
and greater efficacy. Some deliver
multiple drugs, some carry ligands to9 ª2009 Elsevier Ltd All rights reserved 349
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rate multiple functionalities, and some
incorporate mechanisms to control drug
release. The majority of these are based
either on polymer-drug conjugates or
polymeric micelles, both highly versatile
and flexible design strategies. Notable
among the former is Cell Therapeutics’s
Opaxio, a polymer-paclitaxel conjugate
featured in more than 20 clinical trials for
lung, breast, ovarian, and other cancers.
A notable example of polymeric micelle
is Samyang’s Genexol-PM, another pacli-
taxel formulation, now in a clinical trial for
pancreatic cancer; the drug has already
been approved in South Korea. Nearly
two dozen other formulations are also in
clinical trials.
‘‘We’re learning that there’s a tremen-
dous amount of subtlety in how you
develop these miniaturized delivery
systems,’’ says Alan Crane, chief execu-
tive of Cerulean Pharma, a startup that is
commercializing a second generation
nanoscale delivery technology developed
by MIT researchers. Crane says it is
crucial to be able to control the rate of
drug release; some agents work best
when released in a sudden burst, while
others prefer sustained release. Ceru-
lean’s product, Nanocell, incorporates
both these release modes. On reaching
the tumor, it first discharges a burst of
an antiangiogenic agent to destroy the
tumor vasculature. It then slowly releases
an anticancer compound to destroy the
now-isolated tumor. ‘‘Nanotechnology
allows you to fine tune the release of
your drug to whatever profile you are
trying to achieve,’’ says Crane. ‘‘It allows
you to go beyond chemistry and add
more functionalities to your drug.’’
Tumors often develop drug resistance
by exploiting natural cellular mechanisms
such as efflux pumps to eject drugs
before they can act. One way to combat
this is active targeting. ‘‘The idea is not
just to localize the therapeutic in the
tumor, but to actively take it into the
cell,’’ says Davis. Equipped with the right
ligand, a nanoparticle can use the endo-
cytic pathway to enter a tumor cell and
can thus bypass the cell surface pump350 Chemistry & Biology 16, April 24, 2009 ªmechanisms of drug resistance. This is
particularly beneficial for therapeutics
such as siRNAs that have to be delivered
and released within the cell. Davis has de-
signed a nanoparticle formulation called
CALAA-01 that employs both targeting
aswell as controlled releasemechanisms.
Targeting is achieved by transferrin mole-
cules on the particle’s surface that bind to
the corresponding receptor on cancer
cells. Once inside an endocytic vesicle,
a chemical sensor in the particle reacts
to the ambient acidity to release the
payload of about 2,000 siRNA molecules.
A phase I trial with this nanoparticle began
in May 2008 and is ongoing, says Davis.
Despite these advances, cancer nano-
particles face significant obstacles before
they make it to the clinic. Like any new
medical entity, they pose safety concerns:
for instance, they may provoke an
immune response or breach the blood-
brain barrier. Evidence for such concerns
has so far been minimal, but may emerge
as more trials are conducted. And like any
new medical entity, nanoparticle-based
formulations are likely to be expensive,
particularly the more advanced ones.
‘‘But by far the biggest challenge is
complexity,’’ says Laird Forrest, PhD, an
expert in nanoparticle design at the
University of Kansas. He fears that many
formulations being developed incorpo-
rate so many functions and components
that they may prove unstable and hard
to manufacture on a commercial scale.
‘‘The simple truth is most of them are
never going to be clinically feasible,’’ he
says. ‘‘That may be why big pharma
hasn’t embraced nanotechnology.’’
Investors, however, have shown more
interest. ‘‘The field has great potential,
although the majority of technologies out
there are just incremental,’’ says Nick
Wachtel of Lux Capital Management, an
early stage venture capital firm that
includes Cerulean in its portfolio. Wachtel
says thatbiotechnologygroups that simply
see nanoparticles as a carrier for their
drugs may miss the full potential of the
idea. As investors, ‘‘we’re not interested
in something that will address one specific
issue for a cancer drug,’’ he says. ‘‘We’re2009 Elsevier Ltd All rights reservedlooking for new ideas, new architectures,
clever engineering approaches, technolo-
gies thatwill dramatically impact thewhole
of drug delivery.’’
Also on the hunt for breakthrough tech-
nologies is the Nanotechnology Institute,
a nonprofit based in Philadelphia that
assists drug commercialization by
promoting industry–university partner-
ships. ‘‘Cancer therapy is still very unfo-
cused, both literally and figuratively,’’
says Anthony Green, PhD, who directs
the institute. ‘‘By going nano, you can get
much more bang for the buck.’’ The insti-
tute has invested in several nanotech-
nology companies including Keystone
Nano, a startup that makes a drug-
carrying nanoparticle built from a calcium
phosphate matrix. Green is not surprised
at nanoparticles’ modest clinical track
record; he likens the present state of the
field with the early, setback-plagued
days of monoclonal antibodies. ‘‘Mono-
clonals took almost 15 years before the
first productwas approved,’’ notesGreen.
‘‘We are maybe only 10 years into nano.’’
Once nanoparticle-based delivery has
matured into a safe, reliable, and practical
scheme, it could play a pivotal role in
cancer therapy, says Neal Davies, PhD,
a pharmacologist at theWashington State
University in Pullman who evaluates the
safety of nanoparticle-based drugs. ‘‘We
can dramatically improve the treatment
of some cancers, such as pancreatic
and primary liver, for which there are not
many other options,’’ says Davies. ‘‘Look-
ing into my crystal ball, I see the potential
for major breakthroughs with this
technology.’’
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